Related content

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes

By Miura M.   Tada H.   Yasui-Furukori N.   Uno T.   Sugawara K.   Tateishi T.   Suzuki T.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 9, 2004-11 ,pp. : 623-628

Springer Publishing Company

Access to resources Recommend Favorite

The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype

By Al-Shurbaji Ayman   Säwe Juliette  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 12, 2002-02 ,pp. : 877-881

Springer Publishing Company

Access to resources Recommend Favorite

Hydroxylation of R (+)- and S (−)-Omeprazole after Racemic Dosing are Different among the CYP2C19 Genotypes

By Shiohira Hideo  

Pharmaceutical Research, Vol. 29, Iss. 8, 2012-08 ,pp. : 2310-2316

Springer Publishing Company

Access to resources Recommend Favorite

Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations

By Uno Tsukasa   Niioka Takenori   Hayakari Makoto   Yasui-Furukori Norio   Sugawara Kazunobu   Tateishi Tomonori  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 2, 2007-02 ,pp. : 143-149

Springer Publishing Company

Access to resources Recommend Favorite

A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation

By  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 5, 2015-01 ,pp. : 306-309

Govi-Verlag

Access to resources Recommend Favorite